Earnings ·
Reports Q3 net loss of $0.30 per share and raises $4.3M via ATM program
ELTXElicio Therapeutics, Inc.
Elicio Therapeutics reported a third-quarter 2026 net loss of $8.0 million, or $0.30 per share, compared to a $10.1 million loss in the prior year period. Research and development expenses decreased to $4.9 million from $5.0 million, while general and administrative costs rose to $3.6 million due to increased personnel and professional fees. The company raised net proceeds of $4.3 million through its at-the-market equity program during the quarter, bringing year-to-date proceeds to approximately $28.6 million. Cash and cash equivalents stood at $30.9 million as of September 30, 2026, which management expects will support operations into the second quarter of 2027. The company also highlighted Phase 2 AMPLIFY-7P trial results showing reduced recurrence risk in specific patient subgroups and announced plans to initiate a Phase 1 study for camupepimut combinations in Q4 2026. Elicio Therapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers.